Stay updated on Pembrolizumab in Recurrent PCNSL Clinical Trial
Sign up to get notified when there's something new on the Pembrolizumab in Recurrent PCNSL Clinical Trial page.

Latest updates to the Pembrolizumab in Recurrent PCNSL Clinical Trial page
- Check5 days agoChange DetectedThe page now displays an updated revision tag from v3.6.2 to v3.6.3, indicating a recent backend/frontend update to the page.SummaryDifference0.1%

- Check12 days agoChange DetectedRevision: v3.6.2 replaces v3.6.0 on the page, indicating an updated build of the site's software or content management. The update reflects a software version change rather than substantive changes to the study details.SummaryDifference0.1%

- Check19 days agoNo Change Detected
- Check26 days agoChange DetectedNew entries identify the investigator and sponsoring institution (Prof. Dr. Matthias Preusser; Medical University of Vienna) and add user-focused navigation items (How to Read a Study Record, Common Questions, How to Join a Study). Additionally, the page labels are updated (Intervention/Treatment) and a new revision tag (Revision: v3.6.0) is introduced.SummaryDifference2%

- Check33 days agoChange DetectedThe page now shows revision v3.5.5, replacing the previous v3.5.4. This update reflects a new page/template version rather than changes to substantive content.SummaryDifference0.1%

- Check54 days agoChange DetectedRevision: v3.5.4 replaces the prior v3.5.3, signaling a small metadata update. This change does not modify any study details, eligibility criteria, or results on the page.SummaryDifference0.1%

- Check76 days agoChange DetectedThe page’s displayed revision/version number was updated from v3.5.2 to v3.5.3, reflecting a website release rather than a change to the underlying study information.SummaryDifference0.1%

Stay in the know with updates to Pembrolizumab in Recurrent PCNSL Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pembrolizumab in Recurrent PCNSL Clinical Trial page.